Bristol-Myers Squibb Holdings Ireland UnLtd Company v Norton [Waterford] Ltd trading as Teva Pharmaceuticals Ireland (Approved) [2023] IEHC 744 (08 December 2023)

Bristol-Myers Squibb Holdings Ireland UnLtd Company v Norton [Waterford] Ltd trading as Teva Pharmaceuticals Ireland (Approved) [2023] IEHC 744 (08 December 2023)

The assignments from inventors to BMS Pharma and subsequently from BMS Pharma to BMS Company were effective to transfer the legal interest in the patent rights, but only to the extent of the rights actually held by the assignor at each stage. The evidence demonstrates that BMS Company exercised control over BMS Pharma's intellectual property assets, and the chain of title is sufficient for priority purposes. Internal policies and manuals, while sometimes inconsistently followed, do not override the effect of executed assignments and corporate control.

Citation
[2023] IEHC 744
Parties
Claimant: Bristol-Myers Squibb Company; Defendant: Teva
Jurisdiction
Ireland
Judgment Date
08 December 2023
Procedural Posture
Intellectual Property Dispute / Trial Oral Evidence and Cross Examination
Outcome
claimant's chain of title and priority rights upheld
Legal Topics
Patent Assignment, Priority Rights, Corporate Governance, Equitable Ownership
Intellectual Property Corporate Law Patent Assignment Priority Rights Corporate Governance Equitable Ownership

Case Brief

Summary, issues, holding and outcome

More case intelligence is available

Unlock the full research layer for this judgment.

Full judgment text Downloadable case file Legal principles 3 Authorities cited 3 Party arguments 2
Sign in to unlock

Parties

Bristol-Myers Squibb Company

Claimant

Teva

Defendant

Procedural Posture

Intellectual Property Dispute / Trial Oral Evidence and Cross Examination

Legal Issues

  1. 1 Whether assignments of patent rights from inventors to BMS Pharma and subsequently to BMS Company were effective to transfer legal and/or equitable title
  2. 2 Whether BMS Company had control over BMS Pharma's intellectual property assets
  3. 3 Whether the chain of title for the patent in suit was properly established for priority purposes

Ratio Decidendi

The assignments from inventors to BMS Pharma and subsequently from BMS Pharma to BMS Company were effective to transfer the legal interest in the patent rights, but only to the extent of the rights actually held by the assignor at each stage. The evidence demonstrates that BMS Company exercised control over BMS Pharma's intellectual property assets, and the chain of title is sufficient for priority purposes. Internal policies and manuals, while sometimes inconsistently followed, do not override the effect of executed assignments and corporate control.

Court Disposition

claimant's chain of title and priority rights upheld

Orders

  • No further orders necessary regarding assignment validity
  • Proceed to determination of substantive patent issues